

Anastasios Dimou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4287127/publications.pdf>

Version: 2024-02-01

11
papers

172
citations

1683354

5
h-index

1281420

11
g-index

11
all docs

11
docs citations

11
times ranked

352
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | HLA Class I Binding of Mutant EGFR Peptides in NSCLC Is Associated With Improved Survival. <i>Journal of Thoracic Oncology</i> , 2021, 16, 104-112. | 0.5 | 6 |
| 2 | Real-world characteristics and outcomes of advanced non-small-cell lung cancer patients with EGFR exon 19 deletions or exon 21 mutations. <i>Future Oncology</i> , 2021, 17, 2867-2881. | 1.1 | 5 |
| 3 | The immunologic balance. <i>Melanoma Research</i> , 2021, Publish Ahead of Print, . | 0.6 | 1 |
| 4 | The Role of GSK3 β in T Lymphocytes in the Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2020, 10, 1221. | 1.3 | 7 |
| 5 | Changing paradigm in advanced and metastatic non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 6992-7001. | 0.6 | 3 |
| 6 | Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 510. | 1.3 | 3 |
| 7 | Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma. <i>BMC Cancer</i> , 2020, 20, 177. | 1.1 | 4 |
| 8 | Detection of NRG1 Fusions in Solid Tumors: Rare Gold?. <i>Clinical Cancer Research</i> , 2019, 25, 4865-4867. | 3.2 | 8 |
| 9 | Inhibition of the Hedgehog pathway in lung cancer. <i>Lung Cancer</i> , 2019, 133, 56-61. | 0.9 | 13 |
| 10 | ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Periagnosis Thromboembolic Events. <i>Journal of Thoracic Oncology</i> , 2019, 14, 596-605. | 0.5 | 56 |
| 11 | Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-L1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer. <i>Cancer</i> , 2019, 125, 1038-1049. | 2.0 | 66 |